Safety and Activity of CTX130, a CD70-Targeted Allogeneic CRISPR-Cas9-Engineered CAR T-Cell Therapy, in Patients with Relapsed or Refractory T-Cell Malignancies (COBALT-LYM): A Single-Arm, Open-Label, Phase 1, Dose-Escalation Study

By
Jamie Kang
-
0
437
Researchers assessed the safety and activity of CTX130, a CD70-directed, allogeneic CAR immunotherapy manufactured from healthy donor T cells, in patients with relapsed or refractory T cell lymphoma.
[Lancet Oncology]
Abstract